Loading...
Targets of opportunity for precision medicine
In this issue of Blood, Schinke et al have identified a higher expression of CXCR2 in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) stem cells than in normal hematopoietic stem cells (HSCs) and demonstrated preclinical therapeutic proof of principle.(1)
Na minha lista:
| Udgivet i: | Blood |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4432001/ https://ncbi.nlm.nih.gov/pubmed/25977578 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2015-04-638270 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|